A Study of LY3561774 in Participants With Mixed Dyslipidemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.
Also called NCT05256654
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 205 participants
- Sponsor
- Registry
-
NCT05256654 -
2021-005407-13
-
- Other papers using this trial's data
- Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Canada, Japan, Mexico, Poland, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT05256654. Randomized; double masking; primary purpose treatment. Start 2022-07-20 (actual); primary completion 2024-03-04 (actual). Results posted on 2025-03-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY3561774 in Participants With Mixed Dyslipidemia
- Acronym
- PROLONG-ANG3
- Condition
- Dyslipidemias
- Condition
- Lipid Metabolism Disorders
- Condition
- Metabolic Diseases
- Condition
- Hyperlipoproteinemia
- Intervention (Drug)
- LY3561774
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05256654- Content hash
10adb8c5f430ba14da0dd2b459ecd4b38f6f6c64eba0bbda75ce44a07886b592